Citadel Advisors’s Xenetic Biosciences XBIO Stock Holding History
Bought
Maintained
Sold
Other funds holding XBIO
Citadel Advisors's XBIO Position: Q3 2026 in Review
Citadel Advisors opened a new position in Xenetic Biosciences (XBIO) in Q3 2026: 15,346 shares worth $35.6K. The stake represents ﹤0.01% of the portfolio and ranks #13522 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in XBIO as recently as Q4 2025.
Citadel Advisors first reported a position in XBIO in Q1 2018 and has held it in 11 quarters since. The position peaked at $201K in Q1 2021. 14 funds tracked by Wall St. Rank hold XBIO as of Q3 2026.
- Citadel Advisors held 15,346 shares of Xenetic Biosciences worth $35.6K as of Q3 2026.
- Xenetic Biosciences was a new Citadel Advisors position in Q3 2026.
- Xenetic Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #13522 holding.
- Citadel Advisors first reported a position in Xenetic Biosciences in Q1 2018 and has held it in 11 quarters since.
- Citadel Advisors's Xenetic Biosciences position peaked at $201K in Q1 2021.
- 14 funds tracked by Wall St. Rank held Xenetic Biosciences as of Q3 2026.
Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.